SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                 SCHEDULE 14D-1

               TENDER OFFER STATEMENT PURSUANT TO SECTION 14(d)(1)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                                 FINAL AMENDMENT



                                   AMGEN INC.
                            (Name of Subject Company)


                              PHARMAINVEST, L.L.C.
                        PHARMACEUTICAL ROYALTIES, L.L.C.
                     PHARMACEUTICAL ROYALTY INVESTMENTS LTD.
                         PHARMACEUTICAL PARTNERS, L.L.C.
                                    (Bidders)


       CONTRACTUAL CONTINGENT PAYMENT RIGHTS ARISING FROM THE PURCHASE OF
               CLASS A INTERESTS OF AMGEN CLINICAL PARTNERS, L.P.
                         (Title of Class of Securities)

                                      NONE
                                 (CUSIP Number)




                          PABLO LEGORRETA, DAVE MADDEN
                              PHARMAINVEST, L.L.C.
                          675 Third Avenue, Suite 3000
                               New York, NY 10017
                                 (800) 600-1450

                                 ---------------




                                   COPIES TO:
                             F. GEORGE DAVITT, ESQ.
                         TESTA, HURWITZ & THIBEAULT, LLP
                                 125 High Street
                                Boston, MA 02110
                                 (617) 248-7000










         This Final Amendment amends and supplements the Tender Offer Statement
on Schedule 14D-1, as amended, filed by PharmaInvest, L.L.C., a Delaware limited
liability company (the "Purchaser"), on behalf of Pharmaceutical Royalties,
L.L.C., a Delaware limited liability company, and Pharmaceutical Royalty
Investments Ltd., a Bermuda company (collectively the "Funds"), and on behalf of
Pharmaceutical Partners, L.L.C., a Delaware limited liability company and the
sole member of Purchaser, relating to the offer by Purchaser to purchase
outstanding contractual contingent payment rights arising from the purchase of
Class A Interests of Amgen Clinical Partners, L.P. (the "CCPRs"), at $220,000
per CCPR, net to the seller in cash, without interest thereon, on the terms and
subject to the conditions set forth in the Offer to Purchase, dated September
29, 1999 (the "Offer to Purchase"), and in the related Letter of Transmittal,
copies of which are attached hereto as Exhibits (a)(1) and (a)(2), respectively
(which, together with any amendments or supplements hereto or thereto,
collectively constitute the "Offer").

         The Offer expired at 12:00 midnight (Eastern Standard Time) on October
29, 1999.

         At the time of expiration, 2.375 CCPRs had been tendered and not
withdrawn. Purchaser has accepted for payment all tendered CCPRs, payment for
which will be made promptly.








                                   SIGNATURES


         After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.


Dated:  November 3, 1999

                              PHARMAINVEST, L.L.C.

                              By:  /s/ David Madden
                                   ---------------------------------------
                                   Name:    David Madden
                                   Title:   Managing Member of
                                            Pharmaceutical Partners, L.L.C.,
                                            the Manager


                              PHARMACEUTICAL ROYALTIES, L.L.C.

                              By:  /s/ David Madden
                                   ---------------------------------------
                                   Name:    David Madden
                                   Title:   Managing Member of
                                            Pharmaceutical Partners, L.L.C.,
                                            the Manager


                              PHARMACEUTICAL ROYALTY INVESTMENTS LTD.

                              By:  /s/ David Madden
                                   ---------------------------------------
                                   Name:    David Madden
                                   Title:   Managing Member of
                                            Pharmaceutical Partners, L.L.C.,
                                            the Manager


                              PHARMACEUTICAL PARTNERS, L.L.C.

                              By:  /s/ David Madden
                                   ---------------------------------------
                                   Name:    David Madden
                                   Title:   Managing Member